Matthew Dai

Currently, I focus on individual stock research, analyzing company fundamentals, competitive positioning, and market dynamics before making decisions. While this approach has led to some wins like Richtech Robotics, I've also learned from losses like ATYR that even thorough research can't eliminate all risk. If a trial for a biotech company fails, the stock will plunge and I think this might be...